New development of a selective oncolytic virotherapy for gastric cancer

点击翻译按钮获取中文摘要

We developed recombinant oncolytic herpes simplex viruses that possess certain antitumor functions and are useful for gastric cancer therapy. A third-generation oncolytic herpes simplex virus type 1(T-01) was used as the backbone to insert foreign sequences. Oncolytic herpes simplex viruses expressing suppressor of cytokine signaling 3 (T-SOCS-3) were constructed, evaluated, and proved to be therapeutic potential. T-SOCS-3 may be a new agent against gastric cancer in the near future, and a progress has been made in the basic development of next generation onoclytic virotherapy.